Warning! GuruFocus detected
4 Severe warning signs
with 9VC.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
ATAI Life Sciences NV
ISIN : NL0015000DX5
Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.61 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.83 | |||||
| Beneish M-Score | 0.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27.6 | |||||
| 3-Year EPS without NRI Growth Rate | 14.9 | |||||
| 3-Year FCF Growth Rate | -57.7 | |||||
| 3-Year Book Growth Rate | 34.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.9 | |||||
| 9-Day RSI | 34.32 | |||||
| 14-Day RSI | 38.92 | |||||
| 3-1 Month Momentum % | 83.31 | |||||
| 6-1 Month Momentum % | 110.57 | |||||
| 12-1 Month Momentum % | 51.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.81 | |||||
| Quick Ratio | 5.81 | |||||
| Cash Ratio | 4.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3 | |||||
| Shareholder Yield % | -1.56 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -31092.15 | |||||
| Net Margin % | -38852.87 | |||||
| FCF Margin % | -23918.57 | |||||
| ROE % | -61.51 | |||||
| ROA % | -50.07 | |||||
| ROIC % | -91.48 | |||||
| 3-Year ROIIC % | -34.78 | |||||
| ROC (Joel Greenblatt) % | -4268.63 | |||||
| ROCE % | -52.3 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 740 | |||||
| PB Ratio | 1.71 | |||||
| Price-to-Tangible-Book | 1.71 | |||||
| EV-to-EBIT | -1.81 | |||||
| EV-to-Forward-EBIT | -0.86 | |||||
| EV-to-EBITDA | -1.81 | |||||
| EV-to-Forward-EBITDA | -1.81 | |||||
| EV-to-Revenue | 681.55 | |||||
| EV-to-Forward-Revenue | 300 | |||||
| EV-to-FCF | -2.82 | |||||
| Price-to-GF-Value | 0.67 | |||||
| Price-to-Net-Current-Asset-Value | 3.95 | |||||
| Price-to-Net-Cash | 7.44 | |||||
| Earnings Yield (Greenblatt) % | -55.25 | |||||
| FCF Yield % | -27.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ATAI Life Sciences NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.307 | ||
| EPS (TTM) (€) | -0.735 | ||
| Beta | 0.87 | ||
| 3-Year Sharpe Ratio | -0.3 | ||
| 3-Year Sortino Ratio | -0.45 | ||
| Volatility % | 80.43 | ||
| 14-Day RSI | 38.92 | ||
| 14-Day ATR (€) | 0.119336 | ||
| 20-Day SMA (€) | 1.660225 | ||
| 12-1 Month Momentum % | 51.68 | ||
| 52-Week Range (€) | 0.9504 - 2.481 | ||
| Shares Outstanding (Mil) | 193.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ATAI Life Sciences NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ATAI Life Sciences NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ATAI Life Sciences NV Frequently Asked Questions
What is ATAI Life Sciences NV(FRA:9VC)'s stock price today?
The current price of FRA:9VC is €1.26. The 52 week high of FRA:9VC is €2.48 and 52 week low is €0.95.
When is next earnings date of ATAI Life Sciences NV(FRA:9VC)?
The next earnings date of ATAI Life Sciences NV(FRA:9VC) is 2025-05-15 Est..
Does ATAI Life Sciences NV(FRA:9VC) pay dividends? If so, how much?
ATAI Life Sciences NV(FRA:9VC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers